I-Tech AB (ITECH.ST)
SEK 54.5
(-1.8%)
SEK 54.5
(-1.8%)
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2023 | 27.56 Million SEK | -38.91% |
| 2022 | 45.12 Million SEK | 64.24% |
| 2021 | 27.47 Million SEK | 9.12% |
| 2020 | 25.18 Million SEK | 18.83% |
| 2019 | 21.19 Million SEK | 106.1% |
| 2018 | 10.28 Million SEK | 79.22% |
| 2017 | 5.73 Million SEK | 7.05% |
| 2016 | 5.35 Million SEK | 165.37% |
| 2015 | -8.19 Million SEK | 0.0% |
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2024 Q2 | 10.9 Million SEK | 19.19% |
| 2024 Q3 | 21.3 Million SEK | 95.46% |
| 2024 Q1 | 9.14 Million SEK | 1279.64% |
| 2023 Q1 | 16.28 Million SEK | 2.54% |
| 2023 FY | 27.56 Million SEK | -38.91% |
| 2023 Q4 | 663 Thousand SEK | -96.05% |
| 2023 Q3 | 16.8 Million SEK | -3.15% |
| 2023 Q2 | 17.35 Million SEK | 6.54% |
| 2022 Q1 | 7.9 Million SEK | 25.38% |
| 2022 FY | 45.12 Million SEK | 64.24% |
| 2022 Q4 | 15.88 Million SEK | 41.21% |
| 2022 Q3 | 11.24 Million SEK | 11.39% |
| 2022 Q2 | 10.09 Million SEK | 27.73% |
| 2021 Q1 | 7.49 Million SEK | 38.88% |
| 2021 Q3 | 7.18 Million SEK | 10.7% |
| 2021 Q4 | 6.3 Million SEK | -12.31% |
| 2021 FY | 27.47 Million SEK | 9.12% |
| 2021 Q2 | 6.49 Million SEK | -13.3% |
| 2020 Q4 | 5.39 Million SEK | -11.95% |
| 2020 Q3 | 6.12 Million SEK | -19.52% |
| 2020 Q1 | 6.05 Million SEK | -13.3% |
| 2020 FY | 25.18 Million SEK | 18.83% |
| 2020 Q2 | 7.61 Million SEK | 25.76% |
| 2019 Q2 | 5.66 Million SEK | 109.32% |
| 2019 FY | 21.19 Million SEK | 106.1% |
| 2019 Q4 | 6.98 Million SEK | 19.44% |
| 2019 Q3 | 5.84 Million SEK | 3.21% |
| 2019 Q1 | 2.7 Million SEK | -43.14% |
| 2018 Q2 | 2.8 Million SEK | 145.1% |
| 2018 FY | 10.28 Million SEK | 79.22% |
| 2018 Q3 | 1.57 Million SEK | -43.79% |
| 2018 Q1 | 1.14 Million SEK | -50.02% |
| 2018 Q4 | 4.75 Million SEK | 201.84% |
| 2017 Q3 | 1.58 Million SEK | -6.28% |
| 2017 Q1 | 117 Thousand SEK | 0.0% |
| 2017 Q2 | 1.68 Million SEK | 1341.88% |
| 2017 Q4 | 2.28 Million SEK | 44.78% |
| 2017 FY | 5.73 Million SEK | 7.05% |
| 2016 FY | 5.35 Million SEK | 165.37% |
| 2015 FY | -8.19 Million SEK | 0.0% |
| Name | Gross Profit | Gross Profit Difference |
|---|---|---|
| Alligator Bioscience AB (publ) | -160.68 Million SEK | 117.155% |
| Ziccum AB (publ) | -23.28 Million SEK | 218.38% |
| Modus Therapeutics Holding AB (publ) | - SEK | -Infinity% |
| BioArctic AB (publ) | 346.31 Million SEK | 92.04% |
| Sprint Bioscience AB (publ) | 41.78 Million SEK | 34.032% |
| Mendus AB (publ) | 28.48 Million SEK | 3.233% |
| Genovis AB (publ.) | 54 Million SEK | 48.953% |
| Intervacc AB (publ) | -13.79 Million SEK | 299.841% |
| QuiaPEG Pharmaceuticals Holding AB (publ) | 2.17 Million SEK | -1169.737% |
| Active Biotech AB (publ) | -1.67 Million SEK | 1745.731% |
| Magle Chemoswed Holding AB (publ) | 9.96 Million SEK | -176.684% |
| Bio-Works Technologies AB (publ) | 26.82 Million SEK | -2.778% |
| Aptahem AB (publ) | 2.63 Million SEK | -947.879% |
| Vicore Pharma Holding AB (publ) | -3.42 Million SEK | 905.788% |
| Kancera AB (publ) | -1.96 Million SEK | 1502.85% |
| Infant Bacterial Therapeutics AB (publ) | 77 Thousand SEK | -35700.0% |
| Fluicell AB (publ) | 1.73 Million SEK | -1486.076% |
| Saniona AB (publ) | 11.78 Million SEK | -133.987% |
| Lipigon Pharmaceuticals AB (publ) | -5.11 Million SEK | 638.714% |
| Biovica International AB (publ) | 6.87 Million SEK | -300.843% |
| Spago Nanomedical AB (publ) | -23.28 Million SEK | 218.395% |
| AcouSort AB (publ) | 8.38 Million SEK | -228.597% |
| Xintela AB (publ) | 78 Thousand SEK | -35241.026% |
| Abliva AB (publ) | -35.66 Million SEK | 177.296% |
| Egetis Therapeutics AB (publ) | -146.9 Million SEK | 118.765% |
| Karolinska Development AB (publ) | 2.8 Million SEK | -882.045% |
| OncoZenge AB (publ) | 3000.00 SEK | -918766.667% |
| Amniotics AB (publ) | -1.93 Million SEK | 1528.29% |
| 2cureX AB (publ) | -37.48 Million SEK | 173.535% |
| CombiGene AB (publ) | -21.29 Million SEK | 229.474% |
| Asarina Pharma AB (publ) | -423 Thousand SEK | 6616.785% |
| Calliditas Therapeutics AB (publ) | 1.12 Billion SEK | 97.56% |
| Camurus AB (publ) | 1.58 Billion SEK | 98.256% |
| Corline Biomedical AB | 28.38 Million SEK | 2.868% |
| IRLAB Therapeutics AB (publ) | -122.73 Million SEK | 122.46% |
| Isofol Medical AB (publ) | -34.41 Million SEK | 180.099% |
| Hansa Biopharma AB (publ) | 70.95 Million SEK | 61.148% |
| Cyxone AB (publ) | 2.61 Million SEK | -955.764% |
| ExpreS2ion Biotech Holding AB (publ) | 3.4 Million SEK | -710.05% |
| Biosergen AB | -456 Thousand SEK | 6145.175% |
| Cantargia AB (publ) | -3.45 Million SEK | 898.783% |
| NextCell Pharma AB | -43.74 Million SEK | 163.011% |
| Xspray Pharma AB (publ) | -9.19 Million SEK | 399.826% |
| Elicera Therapeutics AB (publ) | 11.21 Million SEK | -145.724% |
| Nanologica AB (publ) | -76 Thousand SEK | 36371.053% |
| SynAct Pharma AB | -778 Thousand SEK | 3643.188% |
| Annexin Pharmaceuticals AB (publ) | -193 Thousand SEK | 14382.902% |
| Stayble Therapeutics AB (publ) | - SEK | -Infinity% |
| LIDDS AB (publ) | -12.92 Million SEK | 313.326% |
| Lipum AB (publ) | 53 Thousand SEK | -51911.321% |
| BioInvent International AB (publ) | 71.46 Million SEK | 61.425% |
| Alzinova AB (publ) | 19.87 Million SEK | -38.704% |
| Oncopeptides AB (publ) | 36.29 Million SEK | 24.059% |
| Pila Pharma AB (publ) | 1.46 Million SEK | -1784.185% |
| Guard Therapeutics International AB (publ) | -15 Thousand SEK | 183873.333% |
| Scandinavian ChemoTech AB (publ) | 1.65 Million SEK | -1562.606% |
| Simris Alg AB (publ) | 2 Million SEK | -1273.493% |
| Diamyd Medical AB (publ) | -3.58 Million SEK | 870.0% |
| Xbrane Biopharma AB (publ) | 35.38 Million SEK | 22.104% |
| Ascelia Pharma AB (publ) | -1.04 Million SEK | 2727.836% |
| Diagonal Bio AB (publ) | 3.13 Million SEK | -779.86% |